Background: It has been reported that first morning specimens are more reliable than random spot specimens to assess 24-hour urinary albumin excretion rate (UAER), especially if albuminuria is expressed as albuminuria to creatininuria ratio. We aimed to investigate the influence of (a) posture and activity and (b) the units to best estimate 24-hour albuminuria. Methods: In this retrospective study, 24-hour UAER was compared to 60 min ‘supine’ and 90 min ‘activity’ albuminuria in 124 patients tested for resistant hypertension. The ability to adjust urinary albumin concentration (UAC) to creatininuria (ACR) or to collection duration (tAER) values in order to increase the reliability of albuminuria values was also analyzed. Results: Compared to 24-hour UAER, UAC (mg/l), tAER (µg/min) and ACR (mg/mmol) during the supine period had a similar concordance rate in normo-, micro- and macroalbuminuric patients. The UAC in the supine period was well related to 24-hour UAER. However, UAC almost doubled during activity. Adjustment to creatininuria improved the correlation between albuminuria during both periods and 24-hour UAER, but mainly during the activity period. Conclusions: Our results confirm that UAC is dependent on physical activity. Correction of UAC by creatininuria (ACR) provides a satisfactory estimation of 24-hour UAER. Thus, for practical reasons, it is advisable to use ACR, where no differences appear to exist, whether a supine urine sample or an activity urine sample is obtained.

Keywords:
Urinary albumin excretion rate, Albuminuria, Urinary albumin concentration, Creatininuria
1.
Chrysochou C, Cheung CM, Durow M, Middleton RJ, Solomon LR, Craig A, et al: Proteinuria as a predictor of renal functional outcome after revascularization in atherosclerotic renovascular disease (ARVD). QJM 2009;102:283–288.
2.
Couchoud C, Lassalle M, Stengel B, Jacquelinet C: Renal Epidemiology and Information Network: 2007 annual report (in French). Nephrol Ther 2009;5(suppl 1):S3–S144.
3.
Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al: Kidney Early Evaluation Program Investigators CKD in the United States. Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(suppl 2):S13–S20.
4.
Grimm RH, Svendsen KH, Kasiske B, Keane WF, Wahi MM: Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 1997;63:S10–S14.
5.
Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325–1333.
6.
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al, Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT) Investigators: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809–2816.
7.
Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS, et al: Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007;167:1386–1392.
8.
Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group: Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 2008;23:3851–3858.
9.
Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198–202.
10.
Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853–906.
11.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al: Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–1187.
12.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154–2169.
13.
National Kidney Foundation: KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Guideline 5. Assessment of Proteinuria. Am J Kidney Dis 2002;39(suppl):S1–S12.
14.
Hutchison AS, O’Reilly DS, MacCuish AC: Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clin Chem 1988;34:2019–2021.
15.
Derhaschnig U, Kittler H, Woisetschläger C, Bur A, Herkner H, Hirschl MM: Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients? Nephrol Dial Transplant 2002;17:81–85.
16.
Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R: First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009;20:436–443.
17.
Heathcote KL, Wilson MP, Quest DW, Wilson TW: Prevalence and duration of exercise induced albuminuria in healthy people. Clin Invest Med 2009;32:E261–E265.
18.
Clerico A, Giammattei C, Cecchini L, Lucchetti A, Cruschelli L, Penno G, et al: Exercise-induced proteinuria in well-trained athletes. Clin Chem 1990;36:562–564.
19.
Tsioufis C, Dimitriadis K, Thomopoulos C, Tsiachris D, Selima M, Stefanadi E, et al: Exercise blood pressure response, albuminuria, and arterial stiffness in hypertension. Am J Med 2008;121:894–902.
20.
Purzycki Z, Wyrzykowski B, Gockowski K, Winnicki MM, Kazmirowicz M, Krupa-Wojciechowska B, et al: The influence of exercise on albumin excretion rate in borderline hypertensives and in offspring of hypertensive parents. J Hum Hypertens 1997;11:119–123.
21.
West JN, Gosling P, Dimmitt SB, Littler WA: Non-diabetic microalbuminuria in clinical practice and its relationship to posture, exercise and blood pressure. Clin Sci (Lond) 1991;81:373–377.
22.
Vittinghus E, Mogensen CE: Albumin excretion and renal haemodynamic response to physical exercise in normal and diabetic man. Scand J Clin Lab Invest 1981;41:627–632.
23.
Viberti GC, Jarrett RJ, McCartney M, Keen H: Increased glomerular permeability to albumin induced by exercise in diabetic subjects. Diabetologia 1978;14:293–300.
24.
Fujita Y, Matoba K, Takeuchi H, Ishii K, Yajima Y: Anaerobic threshold can provoke microalbuminuria in non-insulin-dependent diabetics. Diabetes Res Clin Pract 1994;22:155–162.
25.
American Diabetes Association: Executive summary: standards of medical care in diabetes. Diabetes Care 2009;32(suppl 1):S6–S12.
26.
Marshall SM, Alberti KG: Screening for early diabetic nephropathy. Ann Clin Biochem 1986;23:195–197.
27.
Marshall SM: Screening for microalbuminuria: which measurement? Diabetes Med 1991;8:706–711.
28.
Gatling W, Knight C, Mullee MA, Hill RD: Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabetes Med 1988;5:343–347.
29.
James MA, Fotherby MD, Potter JF: Screening test for microalbuminuria in non-diabetic elderly subjects and their relation to blood pressure. Clin Sci 1995;88:185–190.
30.
National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(suppl):S12–S154.
31.
Brinkman JW, de Zeeuw D, Duker JJ, Gansevoort RT, Kema IP, Hillege HL, et al: Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin Chem 2005;51:2181–2183.
32.
Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997;20:516–519.
33.
Jermendy G, Farkas K, Nadas J, Daroczy A, Peterfai E: Practical aspects of measuring microalbuminuria in diabetic patients. Diabetes Nutr Metab 2001;14:195–200.
34.
Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ: Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005;20:2402–2407.
35.
Ahn CW, Song YD, Kim JH, Lim SK, Choi KH, Kim KR, et al: The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Med J 1999;40:40–45.
36.
Ng WY, Lui KF, Thai AC: Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio. Ann Acad Med Singapore 2000;29:62–65.
37.
Buzio C, Mutti A, Capani F, Andrulli S, Perazzoli F, Alinovi R, Negro A, Rustichelli R: Circadian rhythm of proteinuria: effects of an evening meat meal. Nephrol Dial Transplant 1989;4:266–270.
38.
Phillipou G, Phillips PJ: Variability of urinary albumin excretion in patients with microalbuminuria. Diabetes Care 1994;17:425–427.
39.
Koopman MG, Krediet RT, Koomen GC, Strackee J, Arisz L: Circadian rhythm of proteinuria: consequences of the use of urinary protein:creatinine ratios. Nephrol Dial Transplant 1989;4:9–14.
40.
van Stralen KJ, Stel VS, Reitsma JB, Dekker FW, Zoccali C, Jager KJ: Diagnostic methods I: sensitivity, specificity, and other measures of accuracy. Kidney Int 2009;75:1257–1263.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.